Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OM
OM logo

OM Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
5.170
Open
5.110
VWAP
4.91
Vol
127.22K
Mkt Cap
88.79M
Low
4.780
Amount
625.05K
EV/EBITDA(TTM)
--
Total Shares
18.54M
EV
34.43M
EV/OCF(TTM)
--
P/S(TTM)
0.78
Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
Show More

Events Timeline

(ET)
2026-05-07
16:50:00
Company Reports Q1 Revenue of $27.86M, Below Expectations
select
2026-05-07
16:50:00
Outset Reiterates 2026 Revenue Guidance of $125M to $130M
select
2026-02-11 (ET)
2026-02-11
16:10:00
Outset Medical Reports Q4 Revenue of $28.87M
select
2026-02-11
16:10:00
Outset Provides 2026 Revenue Guidance of $125M to $130M
select
2026-01-27 (ET)
2026-01-27
09:10:00
Outset Medical Receives FDA 510(k) Clearance
select
2026-01-12 (ET)
2026-01-12
08:50:00
Outset Medical Outlook for Continued Growth in 2026
select

News

PRnewswire
7.0
07-06PRnewswire
Outset Medical Faces Securities Fraud Investigation Over Misleading FDA Claims
  • Legal Investigation Initiated: Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Outset Medical, Inc. regarding false statements about FDA clearance requirements for its key products, which could lead to significant investor losses.
  • Lawsuit Progress: U.S. District Judge Edward J. Davila has ruled that key claims in a securities fraud lawsuit against Outset Medical and its executives will proceed, indicating the court's serious consideration of the case.
  • Insider Trading Concerns: During the period from September 2020 to August 2024, company insiders sold over $50 million in stock, suggesting potential misconduct and raising further concerns about corporate governance.
  • Stock Price Plunge Impact: Following the disappointing Q2 2024 results released in August 2024, the stock price plummeted by 68%, reflecting severe market concerns regarding the company's financial health and potentially diminishing investor confidence.
NASDAQ.COM
2.0
07-02NASDAQ.COM
Biotech Companies See Significant Stock Gains
  • Can-Fite Surge: Can-Fite BioPharma Ltd. (CANF) saw its stock soar over 55% to $4.63 following an update on its pancreatic cancer study, where the Phase 2a trial of Namodenoson met primary safety endpoints and showed durable survival outcomes, indicating strong future market potential as the company plans to advance to a Phase 2b combination study with chemotherapy.
  • SeaStar Revenue Growth: SeaStar Medical Holding Corp. (ICU) experienced a stock increase of over 30% to $4.86, driven by no specific news, yet its flagship product QUELIMMUNE received FDA approval in 2024, with projected net product revenue of approximately $2 million in 2026, up from $1.2 million in 2025, reflecting strong market demand in critical care treatments.
  • Elicio Strategic Refinement: Elicio Therapeutics Inc. (ELTX) jumped over 31% to $5.14, as it was added to the Russell 2000 and 3000 Indexes in 2026, despite its EL-002 product not meeting the primary endpoint in the AMPLIFY-7P trial, the company has refined its Phase 3 development strategy based on trial insights and plans to initiate a Phase 3 trial pending financing, showcasing ongoing R&D progress.
  • Regentis European Rollout: Regentis Biomaterials Ltd. (RGNT) rose over 29% to $4.57, with no specific news, but its GelrinC product received CE Mark approval, and the company plans to begin European surgeon training this quarter as part of its commercial rollout preparations, indicating significant market expansion potential in regenerative medicine.
NASDAQ.COM
9.5
06-19NASDAQ.COM
Outset Medical Shares Surge 25.6% on HCA Deal
  • Significant Price Surge: Outset Medical's shares soared 25.6% in the last trading session to close at $5.05, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's future prospects.
  • Key Contract Signing: The company entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, which will purchase new Tablo Hemodialysis Systems from 2026 to 2028 for an aggregate value of approximately $40 million, providing a stable revenue stream for the company.
  • Earnings Report Expectations: Outset Medical is expected to report a quarterly loss of $0.63 per share, representing a year-over-year change of +25%, while revenues are projected at $28.8 million, down 8.3% from the previous year, yet the market remains optimistic about future growth potential.
  • Market Performance Analysis: Although the current EPS estimates have remained unchanged over the past 30 days, the stock's price increase is typically correlated with trends in earnings estimates, prompting investors to monitor Outset Medical's future earnings trends to assess the sustainability of its stock price increase.
Yahoo Finance
5.0
05-28Yahoo Finance
Osisko Metals Annual Meeting Results Announced
  • Shareholder Meeting Voting: At today's annual meeting, a total of 475,369,374 common shares were represented, accounting for approximately 64.4% of the total issued shares, with all proposals approved, indicating strong shareholder support for the management.
  • Auditor Appointment: PricewaterhouseCoopers LLP was appointed as the auditor for the upcoming year, with the board authorized to determine their remuneration, ensuring financial transparency and compliance for the corporation.
  • Board Election Results: All management nominees were successfully elected to the board with support rates as high as 99.97%, reflecting shareholder trust in the current management team and facilitating the smooth implementation of the company's strategic initiatives.
  • New Director Addition: Keith McKay was elected as a director, bringing over 30 years of financial management experience, and his extensive industry knowledge is expected to significantly support the company's expansion in the copper and zinc sectors, enhancing its competitive edge.
NASDAQ.COM
2.0
05-09NASDAQ.COM
Outset Medical (OM) Q4 2025 Earnings Transcript
NASDAQ.COM
2.0
05-07NASDAQ.COM
Outset Medical (OM) Q1 2026 Earnings Transcript
Wall Street analysts forecast OM stock price to rise
4 Analyst Rating
Wall Street analysts forecast OM stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
7.00
Averages
11.75
High
17.00
Current: 0.000
sliders
Low
7.00
Averages
11.75
High
17.00
TD Cowen
Joshua Jennings
Buy
downgrade
$12 -> $10
AI Analysis
2026-05-08
Reason
TD Cowen
Joshua Jennings
Price Target
$12 -> $10
AI Analysis
2026-05-08
downgrade
Buy
Reason
TD Cowen analyst Joshua Jennings lowered the firm's price target on Outset Medical to $10 from $12 and keeps a Buy rating on the shares.
Stifel
Buy
to
Buy
downgrade
$8 -> $6
2026-05-08
Reason
Stifel
Price Target
$8 -> $6
2026-05-08
downgrade
Buy
to
Buy
Reason
Stifel lowered the firm's price target on Outset Medical to $6 from $8 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OM
Unlock Now

Valuation Metrics

The current forward P/E ratio for Outset Medical Inc (OM.O) is 0.00, compared to its 5-year average forward P/E of -6.88. For a more detailed relative valuation and DCF analysis to assess Outset Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.88
Current PE
0.00
Overvalued PE
-0.97
Undervalued PE
-12.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.79
Current EV/EBITDA
-1.92
Overvalued EV/EBITDA
-0.51
Undervalued EV/EBITDA
-11.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.62
Current PS
0.62
Overvalued PS
11.69
Undervalued PS
-0.46

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

low float medical tech stock
Intellectia · 68 candidates
Market Cap: 50.00M - 5.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchRegion: USPrice: $1.00 - $50.00Beta: ModerateRisk, HighRisk, LowRisk, NegativeBetaList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000Floating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
XLO logo
XLO
Xilio Therapeutics Inc
50.19M
LPCN logo
LPCN
Lipocine Inc
54.02M
LFVN logo
LFVN
LifeVantage Corp
54.88M
CLNN logo
CLNN
Clene Inc
63.49M
OM logo
OM
Outset Medical Inc
64.46M
ACET logo
ACET
Adicet Bio Inc
64.58M
which crypto had highest buyers today
Intellectia · 1018 candidates
Turnover 24h: >= 1
Ticker
Name
Market Cap$
top bottom
BTC logo
BTC
Bitcoin
1.36T
ETH logo
ETH
Ethereum
238.14B
USD1 logo
USD1
World Liberty Financial USD
5.02B
SOL logo
SOL
Solana
48.39B
XRP logo
XRP
XRP
87.23B
BNB logo
BNB
BNB
85.23B
go below 60
Intellectia · 1018 candidates
Ticker
Name
Market Cap$
top bottom
BTC logo
BTC
Bitcoin
1.32T
ETH logo
ETH
Ethereum
233.78B
XRP logo
XRP
XRP
86.49B
BNB logo
BNB
BNB
82.22B
SOL logo
SOL
Solana
46.07B
TRX logo
TRX
TRON
26.38B
cryptos under $1
Intellectia · 949 candidates
Price: <= $1.00
Ticker
Name
Market Cap$
top bottom
TRX logo
TRX
TRON
26.32B
DOGE logo
DOGE
Dogecoin
15.66B
ADA logo
ADA
Cardano
9.45B
USDE logo
USDE
USDe
6.42B
CC logo
CC
Canton Network
6.39B
USD1 logo
USD1
World Liberty Financial USD
5.37B
crypto under 1 dollar
Intellectia · 936 candidates
Price: <= $1.00
Ticker
Name
Market Cap$
top bottom
TRX logo
TRX
TRON
26.97B
DOGE logo
DOGE
Dogecoin
17.07B
ADA logo
ADA
Cardano
10.24B
CC logo
CC
Canton Network
6.61B
USDE logo
USDE
USDe
6.55B
XLM logo
XLM
Stellar
5.67B
high risk investments, or crypto
Intellectia · 483 candidates
Turnover 24h: >= 100,000Market Cap: 5.00M - 1000.00M
Ticker
Name
Market Cap$
top bottom
FIGHT logo
FIGHT
FIGHT
48.73M
SKR logo
SKR
SKR
237.08M
ELSA logo
ELSA
ELSA
37.65M
SENT logo
SENT
SENT
220.90M
YZY logo
YZY
YZY MONEY
100.82M
XRD logo
XRD
Radix
43.68M
tell me a stock ticker that is a buy now
Intellectia · 24 candidates
Analyst Consensus: Strong BuyPe Ttm: <= 20Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $15.00Annual Eps Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
ATGE logo
ATGE
Adtalem Global Education Inc
4.42B
ARDX logo
ARDX
Ardelyx Inc
1.94B
OCS logo
OCS
Oculis Holding AG
1.51B
DAWN logo
DAWN
Day One Biopharmaceuticals Inc
1.24B
ANNX logo
ANNX
Annexon Inc
1.02B
CTMX logo
CTMX
CytomX Therapeutics Inc
896.31M

Whales Holding OM

G
GMT Capital Corp.
Holding
OM
+9.00%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Outset Medical Inc (OM) stock price today?

The current price of OM is 4.79 USD — it has decreased -5.71

What is Outset Medical Inc (OM)'s business?

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.

What is the price predicton of OM Stock?

Wall Street analysts forecast OM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OM is11.75 USD with a low forecast of 7.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Outset Medical Inc (OM)'s revenue for the last quarter?

Outset Medical Inc revenue for the last quarter amounts to 27.86M USD, decreased -6.35

What is Outset Medical Inc (OM)'s earnings per share (EPS) for the last quarter?

Outset Medical Inc. EPS for the last quarter amounts to -1.03 USD, decreased -71.86

How many employees does Outset Medical Inc (OM). have?

Outset Medical Inc (OM) has 310 emplpoyees as of July 08 2026.

What is Outset Medical Inc (OM) market cap?

Today OM has the market capitalization of 88.79M USD.